A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers Read more about A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment Read more about A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Read more about A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Read more about Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease Read more about Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy Read more about Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
Sleep for Stroke Management and Recovery Trial Read more about Sleep for Stroke Management and Recovery Trial
5-Cog Battery for Detecting Cognitive Impairment and Dementia Read more about 5-Cog Battery for Detecting Cognitive Impairment and Dementia
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) Read more about Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)